J. Christopher Naftzger

Chris Naftzger joined Krystal Biotech as its Chief Legal Officer and Corporate Secretary in February 2020. Prior to joining Krystal, he was Vice President, Deputy General Counsel and Assistant Secretary of Nabriva Therapeutics plc (NASDAQ: NBRV), where he was part of the team that transformed Nabriva from a clinical-stage to commercial-stage pharmaceutical company, with the launch of its lead product, XENLETATM, the first new systemic class of antibiotic approved in the U.S. in nearly two decades. He also served as Vice President, General Counsel, Chief Compliance Officer, and Secretary of Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a developer and manufacturer of innovative drug delivery systems, where he was the company’s first general counsel and established the corporate legal and compliance functions following Unilife’s listing on NASDAQ. Previously, Chris held senior in-house counsel positions with Chesapeake Corporation (NYSE: CSK) and Koch Industries. After law school, Chris worked as a corporate associate at Dyer Ellis & Joseph, P.C. in Washington, DC, where he became a partner upon the firm’s merger with Blank Rome LLP. Chris obtained his undergraduate degree from Hampden-Sydney College and his law degree from the Willamette University College of Law, where he served as managing editor of the Willamette Law Review.